BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink

[cafead]

via As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. Meanwhile, those pharmas facing greater generic threats in the coming decade may be more inclined to pick up earlier-stage candidates from beyond their own pipelines.

article source